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Abstract Galectin-3 is a member of the galectin family,
which consists of animal lectins that bind β-galactosides.
Recently, a role for galectin-3 in the pathophysiology of
heart failure has been suggested. It was observed that
galectin-3 is specifically upregulated in decompensated
heart failure compared with compensated heart failure in
animal models of heart failure. This has been associated
with activation of fibroblasts and macrophages, which are a
hallmark of cardiac remodeling. Therefore, galectin-3 may
be a culprit biomarker in heart failure. Initial clinical
observations indicate that galectin-3 may be a useful
biomarker for decompensated heart failure, with incremen-
tal value over well-used “pressure-dependent” biomarkers,
such as B-type natriuretic peptide. Future studies should
focus on galectin-3 biology to better address the usefulness
of galectin-3 as a biomarker and probe the usefulness of
anti-galectin-3 therapy in treating heart failure.
Keywords Galectin3.Heartfailure.Prognosis.Fibrosis.
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Introduction
Galectins are a family of lectins that bind β-galactosides
[1, 2]. Galectins are expressed in vertebrates such as fish,
birds, amphibians, and mammals, but also in invertebrates
(worms, insects) and even in lower organisms such as
sponge and fungus [1, 2], which suggest an important role
in biology. Currently, 15 members of the galectin family
have been described in vertebrates.
All galectins bind carbohydrate via carbohydrate-
recognition domains (CRDs), with many conserved sequence
elements that are typically about 130 amino acids. Some
galectinscontainjustone CRD(galectins1,2,5,7,10,11,13,
14, and 15), others (tandem repeat-like) galectins contain two
homologousCRDsinasinglepolypeptidechain,separatedby
a linker of up to 70 amino acids (galectins 4, 6, 8, 9, and 12),
whereas galectin-3 contains a nonlectin N-terminal region
(about120aminoacids)connectedtoaCRD,oftenreferredto
as a chimera-like galectin. Each galectin has an individual
carbohydrate-binding preference. Most galectins are bivalent
or multivalent with regard to their carbohydrate-binding
features: one-CRD galectins may form dimers; two-CRD
galectins have two carbohydrate-binding sites; whereas
galectin-3 forms pentamers upon binding to multivalent
carbohydrates. Therefore, galectins can form ordered “arrays”
made of lectin and multivalent glycoconjugates [3, 4••].
Galectins are primarily localized in the cytoplasm, but
can also be localized in the nucleus. Although galectins
can be secreted, they do so without a specific signal
sequence. Galectin family members do not contain a
classical signal sequence. Consistent with this feature, the
proteins are localized primarily in the cytoplasm, although
also in the nucleus under certain conditions. However,
they can be secreted and thus belong to the group of
proteins that do not contain a signal sequence but can
function outside cells [5].
Galectins may bind to different cell surface antigens and
receptors in a carbohydrate-dependent manner. It has been
suggested that galectins may not have specific individual
receptors, but that each galectin can bind to a set of cell
surface or extracellular matrix glycoproteins containing
suitable oligosaccharides. Recent studies have demonstrat-
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signal transduction, by binding to intracellular ligands and
participating in intracellular signaling pathways [6].
Galectin-3: Biology and Expression
Biology
Galectin-3 (sometimes also referred to as Mac-2, carbohydrate-
binding protein [CBP]-35, εB P ,R L - 2 9 ,H L - 2 9 ,L - 3 4 ,o r
lipopolysaccharide-binding protein [LBP]; size: 31KDa) is
found in solution as a monomer with two functional domains
[7–9]. Galectin-3 is unique for having an extra N-terminal
domain of about 100 to 150 amino acids long, rich in proline,
glycine, tyrosine, and glutamine [10]. Galectin-3 has high
affinity for lactose and N-acetyllactosamine; affinity for N-
acetyllactosamine is about fivefold higher than for lactose;
ligands containing poly-N-acetyllactosamine sequences use
galectin-3 as a receptor. Galectin-3 is a unique chimera-like
galectin. This means that galectin-3 consists of carbohydrate
recognition and collagen-like domains, which makes it able to
interact with a wide array of extracellular matrix proteins,
carbohydrates (eg, N-acetyllactosamine), and unglycosylated
molecules, such as cell surface receptors (macrophage
CD11b/CD18) and extracellular receptors (collagen IV).
Galectin-3 mainly binds to glycosylated proteins of the
matrix, including laminin, fibronectin, and tenascin [11, 12].
This has extensively been reviewed by Krzéslak et al. [10]
and Ochieng et al. [13]( T a b l e1).
Galectin-3 is localized in the cytoplasma and the
nucleus. Loss of nuclear galectin-3 is believed to affect
the malignant phenotype of cancers. Nuclear expression of
galectin-3 is associated with proliferative effects and it has
been described that galectin-3 translocates from the cytosol
into the nucleus via a passive and an active pathway [14].
Galectin-3 contains several phosphorylation sites and other
determinants important for the secretion of galectin-3,
which proceeds via a novel, nonclassical pathway [15].
Through its interaction with extracellular matrix proteins,
galectin-3 can cross the plasma membrane despite its lack
of appropriate signal peptides. Secretion of galectin-3 is
critically regulated at the plasma membrane [16].
Expression of Galectin-3
The different members of the galectin family exhibit a
specific pattern of expression in various cells and tissues.
Expression of galectin-3 has been detected in macrophages,
eosinophils, neutrophils, and mast cells [17, 18]. In tissues,
galectin-3 is most abundantly expressed in lung, spleen,
stomach, colon, adrenal gland, uterus, and ovary [19].
Galectin-3 is also expressed, albeit at a much lower level, in
kidney, heart, cerebrum, pancreas, and liver [19]. However,
under pathophysiologic conditions, the level of expression
of galectin-3 may change substantially so that a low
constitutive expression level of galectin-3 does not preclude
a prominent function (eg, in liver and heart).
Galectin-3 in Cardiac Remodeling and Heart Failure
Experimental Observations
The observation that galectin-3 is increased in decompen-
sated heart failure has been published in a seminal paper by
Sharma et al. [20]. The authors studied homozygous Ren-2
rats that overexpress the murine Ren-2d renin gene,
resulting in severe hypertension with end-organ damage
[21, 22]. It was observed that, although some rats
experience overt failure after about 15 weeks, with signs
of heart failure such as dyspnea, lethargy, and severely
compromised hemodynamics, some rats remain compen-
sated. These two groups were compared using a comple-
mentary DNA array with whole RNA from rat hearts. It
was observed that a set of 48 genes were differentially
regulated [20, 23]. Interestingly, most differentially regu-
lated genes typically encoded matricellular proteins, such as
collagens, osteoactivin, and fibronectin, but not loading-
dependent factors, such as natriuretic peptides [23].
Galectin-3 was the strongest regulated gene, being up-
expressed in decompensated hearts more than fivefold
compared with compensated hearts.
To dissect cause from consequence, Sharma et al. [20]
showed that infusion with galectin-3 in the pericardial sac
of normal rats led to the development of cardiac remodeling
with dysfunction and increased expression of collagens.
Given the upregulation of galectin-3 well before the
transition to overt heart failure, the authors concluded that
galectin-3 may be a factor that should be considered as a
novel target for intervention in heart failure.
Thandavarayan et al. [24] recently described a model
with cardiospecific expression of a dominant-negative form
of 14-3-3 protein, which regulates apoptosis and several
signaling pathways that leads to left ventricular (LV)
dysfunction. Besides typical changes for LV remodeling,
such as hypertrophy, fibrosis, and apoptosis, the authors
also describe an upregulation of galectin-3 in the LV [24].
Therefore, upregulation of galectin-3 may be a general
phenomenon in LV dysfunction and not be confined to
models with increased angiotensin II (AngII) signaling.
A potential role in mediating the effects of galectin-3 has
been suggested for N-acetyl-Ser-Asp-Lys-Pro (ac-SDKP), a
tetrapeptide degraded by angiotensin-converting enzyme
(ACE) [25, 26•]. First, researchers showed that differenti-
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inhibited by ac-SDKP. Second, in mice treated with
angiotensin II, ac-SDKP reduced fibrosis and expression
of galectin-3 in LV tissue [25]. In a second study, LV
remodeling was induced by infusion of galectin-3 in the
pericardial sac [26•], with or without coadministration of
ac-SDKP. As in the initial report by Sharma et al. [20],
galectin-3 enhanced macrophage and mast cell infiltration,
which is associated with development of interstitial and
perivascular fibrosis and LV dysfunction. Ac-SDKP pre-
vented these events, in whole or in part, and these effects
were shown to be mediated by transforming growth factor
(TGF-β)/Smad3 pathway.
Fibrosis
Galectin-3 seems to be particularly involved in fibrosis.
Fibrosis and scar formation are pivotal processes in
maladaptive cardiac remodeling. Fibroblasts, myofibroblasts,
and macrophages have been identified as important cells in
the initiation and progression of tissue scarring [27–29].
Various fibrotic conditions are associated with upregulation
of galectin-3: liver cirrhosis [30, 31], idiopathic lung fibrosis
[32], and chronic pancreatitis [33]. In animal models,
upregulation of galectin-3 has been described for hepatic
[31], renal [34, 35•, 36], and cardiac [20, 25, 26•]f i b r o s i s .
More detailed study into the role of galectin-3 in cardiac
remodeling revealed that galectin-3 was localized at the very
sites of fibrosis, colocalizing with fibroblasts and macro-
phages, but not with cardiomyocytes. Galectin-3 binding
sites were visualized by biotinylated antibodies and localized
predominantly to fibrotic areas [20], in line with the evidence
that galectin-3 binds extracellular proteins. Furthermore,
recombinant galectin-3 causes proliferation and collagen
production of cardiac fibroblast cultures in vitro. Other
published data corroborate these observations [25, 26•].
Galectin-3 has also been identified as a potentially
important mediator of removal of advanced glycosylation
end-products (AGEs) [37]. AGEs are molecules formed
during a nonenzymatic reaction between proteins and sugar
residues. They accumulate in the human body with age, but
also with enhanced states of oxidative stress, increased
intake of AGEs, and renal and heart failure, and are thought
to contribute to myocardial stiffening [38]. An AGE-
specific cellular receptor complex (AGE-R) mediating
AGE removal has been described. Galectin-3 interacts with
AGE-R components, thus contributing to the elimination of
these pathogenic substances. Galectin-3 disruption is
associated with increased susceptibility to AGE-induced
renal disease, which indicates that galectin-3 is operating in
vivo as an AGE receptor to afford protection toward AGE-
dependent tissue injury [39, 40]. It remains unknown
whether galectin-3 acts on AGE biology in the heart.
Ligand Source /cells
Extracellular matrix proteins Laminin EHS, macrophage, placenta
Fibronectin Foetal
Tenascin Brain
M2BP Brain
Membrane proteins Integrins Macrophage
αM/β2 (CD11b/18) Adenocarcinoma
α1/β1 Mouse brain
NCAM Mouse brain
L1 Mouse brain
MAG Ubiquitous
LAMP-1/LAMP-2 Rat lens
MP20 Human T lymphoma
CD98 Jurkat cells
Intracellular proteins Cytokeratins HeLa, MCF-7
Chrp Murine T3 fibroblasts
CBP70 HL60
Alix/AIP-1 Human T Lymphoma
Bcl-2 Jurkat cells
Gemin-4 Human T lymphoma
Jurkat cells
HeLa
Others AGE Ubiquitous
Table 1 Ligands for galectin-3
AGE advanced glycation end
products; CBP70 glucose-bind-
ing protein; EHS Engelbroth-
Holm-Swarm tumor
laminin; LAMP lysosomal-
associated membrane protein 1;
M2BP Mac-2 binding protein;
MAG myelin-associated
glycoprotein; MP20 membrane
protein 20; NCAM neural cell
adhesion molecule
(From Krzeslak et al. [10])
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compelling evidence that galectin-3 is a key player in
fibrosis. Especially the generation of galectin-3 deficient
mice has been instrumental in the study of galectin-3 in
fibrosis. Henderson et al. [31, 35•] has published papers on
the role of galectin-3 in hepatic and renal fibrosis. In the
liver, TGF-β via galectin-3 activates myofibroblasts. In the
kidney, galectin-3 expression and secretion by macrophages
is a major mechanism in renal fibrosis.
Inflammation
Besides fibrosis, galectin-3 plays an important role in the
inflammatory response, which is an important player in
the process of cardiac remodeling [41]. In renal models of
inflammation, galectin-3 has been convincingly linked to
fibrosis and damage [34, 36]. Employing a model of
murine renal fibrosis, Henderson et al. [35•] established
that depletion of macrophages significantly reduced
myofibroblast activation and decreased fibrosis. In the
heart, no direct evidence has been generated for inflam-
matory effects via galectin-3, although Sharma et al. [20]
noted that, besides galectin-3, other genes encoding for
immune factors were differentially regulated. Mice that
constitutively express interferon-γ in their livers develop
myocarditis, with macrophages expressing high levels of
galectin-3 [42].
Clinical Studies
Sharmaetal.[20] provided the first report in human subjects.
They studied ventricular biopsies from patients with aortic
stenosis with preserved or depressed ejection fraction and
showed that galectin-3 was upregulated in the biopsies from
patients with depressed ejection fraction. van Kimmenade et
al. [43] published the first clinical study that evaluated the
potential role of galectin-3 as a plasma biomarker in heart
failure. In this study, 599 acutely dyspneic subjects were
evaluated with the goal to establish the usefulness of N-
terminal prohormone brain natriuretic peptide (NT-proBNP),
galectin-3, and apelin in diagnosing heart failure and predict-
ing outcome. A blood sample was collected at baseline, and
NT-proBNP, galectin-3, and apelin were measured later. A
total of 209 patients were diagnosed with heart failure. NT-
proBNP was the most powerful predictor for diagnosing heart
failure. Receiver operating characteristic analysis examining
the value of NT-proBNP for the diagnosis acute heart failure
showed an area under the curve (AUC) for NT-proBNP of
0.94 (P<0.0001), whereas the AUC for galectin-3 for the
diagnosis acute heart failure was 0.72 (P < 0.0001). The
difference between NT-proBNP and galectin-3 being highly
significant (P < 0.0001). The optimal cut-off of galectin-3 in
this study was 6.88 ng/mL, which resulted in a reasonable
sensitivity of 80% but a poor specificity of 52% [43]. For
predicting short-term prognosis (60 days, primary end-point
rehospitalization caused by heart failure [n=60] or all-cause
mortality [n = 17]), galectin-3 was the most powerful
predictor: an AUC for galectin-3 of 0.74 (P=0.0001) and
an AUC for NT-proBNP of 0.67 (P = 0.009), with the
difference being borderline significant (P =0 . 0 5 ) .I n
multivariate analysis, galectin-3 was the strongest predictor
for death and the combination of death and rehospitalizations
for heart failure. Remarkably, well-known predictors for
outcome, such as NT-proBNP and renal function, were not
predictive in this study. Nevertheless, this study provides
strong support for the exploration of galectin-3 as a
biomarker that may predict prognosis, whereas its usefulness
in detecting heart failure or adding incremental value (over
currently used clinical correlates and NT-proBNP) in the
diagnostic work-up of heart failure remains unclear.
In a larger study in patients with chronic heart failure
(n = 232), showed that galectin-3 predicts long-term
outcome (mean follow-up, 3.4 y; HR, 1.95; 95% CI,
1.24–3.09; P=0.004; unpublished data, Lok et al.). Because
not many other biomarkers of heart failure were measured,
it is impossible to value the precise role of galectin-3 in this
cohort from this study.
An interesting mechanistic study by Milting et al. [44]
describes the kinetics of galectin-3 in 55 patients with end-
stage heart failure with the need for mechanical circulatory
support (MCS). This small study determined several
biomarkers especially related to myocardial fibrosis and
remodeling. First, the fibrosis-related biomarkers including
Fig. 1 Galectin-3 pathways. The network represents molecular relation-
ships among different gene products. Node shapes indicate the
functional class of the gene product, whereas node colors indicate a
role in general fibrosis (orange) or cardiac fibrosis (green). Edge colors
indicate upregulation or activation (red), downregulation or inhibition
(green), or involvement without clear directionality (yellow). All
relationships are supported by references from the Ingenuity Pathway
Knowledge BaseorkeyreferenceincludedinthereviewbydeBoer etal.
[47•]. ACE angiotensin-converting enzyme; Ac-SDKP N-acetyl-Ser-
Asp-Lys-Pro; AKT1 RAC-α serine/threonine-protein kinase; CCND1
cyclin D1; CDKN1A cyclin-dependent kinase inhibitor 1A; COL1A1
collagen, type I, α-1; COL4A1 collagen α-1(IV); ERK extracellular
signal-regulated kinase; FN1 fibronectin; IL1RL1 interleukin 1 receptor-
like 1; IL33 interleukin 33; INHBA inhibin β A; MMP matrix
metalloproteinase; MYC v-myc myelocytomatosis viral oncogene homo-
log (avian); NADPH nicotinamide adenine dinucleotide phosphate; PI3K
phosphoinositide 3-kinase; PTEN phosphatase and tensin homolog;
PTK2 protein tyrosine kinase 2; TGFB1 transforming growth factor β-
1; TIMP tissue inhibitor of metalloproteinases; TMSB4X thymosin β-4;
TNF tumor necrosis factor; TP53 tumor protein p53; RELA V-rel
reticuloendotheliosis viral oncogene homolog A, nuclear factor of κ light
polypeptide gene enhancer in B-cells 3, p65 (avian). (From de Boer et al.
[47•], with permission.)

4 Curr Heart Fail Rep (2010) 7:1–8galectin-3 were increased compared with controls. Second,
the authors reported that no fibrosis-related biomarkers,
such as tissue inhibitor of metalloproteinases-1 (TIMP-1),
tenascin, osteopontin, or galectin-3, were reduced by MCS;
only the loading-related biomarker BNP was reduced by
MCS. Third, patients who did not survive on MCS,
compared with patients who lived until transplantation,
had higher baseline galectin-3 levels.
A recent study by Lin et al. [45] described the relation
between serum galectin-3 and markers of extracellular
matrix turnover. They studied 106 patients with chronic
heart failure (New York Heart Association class II-III; mean
Curr Heart Fail Rep (2010) 7:1–8 5LV ejection fraction [LVEF], 35±9%). Serum aminotermi-
nal propeptide of procollagen type I (PINP) and type III
(PIIINP), matrix metalloproteinase-2 (MMP-2), and TIMP-
1 were analyzed, along with galectin-3. Galectin-3 was
correlated with PIIINP, TIMP-1, MMP-2, but not with
LVEF, age, and sex. After correction, the correlation
b e t w e e ng a l e c t i n - 3a n dP I I I N Pa n dM M P - 2r e m a i n e d
statistically significant. The authors conclude that these
findings suggest a relationship between gelactin-3 and
extracellular matrix turnover.
Taken together, from available clinical data, plasma and/
or serum galectin-3 is increased in acute and chronic heart
failure. It seems that galectin-3 may be of particular value to
predict prognosis. However, for clinical diagnosing and/or
decision making, it seems less powerful, although we do not
have sufficient data available.
Conclusions
Galectin-3 is an interesting and complex protein with many
effects in many organs. In the failing or stressed heart, it has
been shown thatactivatedmacrophagessecrete galectin-3.The
increased expression levels of galectin-3 are associated with
the tendency to develop decompensated heart failure, and in
clinical cohorts, increased plasma galectin-3 levels are linked
with worse prognosis. Therefore, galectin-3 may be advocated
as a novel biomarker, but it may also be in the pathophysio-
logic circle of heart failure (“culprit biomarker”), and therefore
it may also be a target for intervention [46•]. The suggested
pathways of galectin-3 are displayed in Fig. 1 [46•].
There are several fields of uncertainty. First, we do not
know how galectin-3 is regulated at a transcriptional and
translational level in the heart. Mechanistic studies have
provided evidence that cardiac fibroblasts and macrophages
are the main sources for galectin-3, and that the TGF-β/Smad
pathway is involved. Inflammatory signals also contribute in
the regulation of galectin-3. However, it remains largely
enigmatic which signals govern the production and secretion
of galectin-3. Second, although several lines of evidence
strongly suggest a contributory role for galectin-3 in the
pathophysiology of heart failure, we lack proof-of-principle
experiments (eg, in galectin-3 deficient mice or in pharmaco-
logic studies) to show that galectin-3 is unequivocally
contributing to the onset and progression of cardiac remodel-
ing.Finally,wehavenodataif therapy,orwhichtherapy,may
affect galectin-3 expression and signaling.
Taken together from available clinical data, plasma and/or
serum galectin-3 is increased in acute and chronic heart
failure. It seems that galectin-3 may be of particular value to
predict prognosis in heart failure; the cause for clinical
diagnosing and/or decision making is less convincing; and to
date we do not have data available to support the use of
galectin-3 for this purpose. Parallel to experiments described
by Sharma et al. [20], we have observed that galectin-3 is
upregulated in compensated and decompensated hypertrophy
compared with healthy control rats; however, the difference
is lesser than when comparing decompensated versus
compensated rats (de Boer, unpublished data). This suggests
that galectin-3 may be of lesser importance during the early
stages of the disease. Furthermore, no data on serial
measurements of galectin-3 have been published. Therefore,
we lack data on half life, kinetics, clearance, and other
parameters of galectin-3 biology. Milting et al. [44]s u g g e s t
that acute unloading by MCS only reduces typical “loading”
biomarkers (ie, BNP [or NT-proBNP]), not so much
biomarkers associated with turnover of the extracellular
matrix, including galectin-3. Most treatment modalities in
heart failure, however, are not acute interventions but chronic
pharmacologic neurohormonal inhibition [47]. Further study
is warranted, however, because it is currently unknown
whether long-term treatments (eg, ACE inhibitors and
aldosterone receptor blockers) intended to reduce matrix
apposition and fibrosis lower galectin-3 levels.
If it is indeed proven that standard treatment of heart
failure is associated with lowering of galectin-3 expression
and levels, one could argue that galectin-3 itself could also
be a target for therapy. Specific agents targeted against
galectins have been tested in small trials with cancer
patients. These agents have not been evaluated in experi-
mental or clinical heart failure, but will likely soon be
tested for their value in this devastating disease.
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